Semaglutide unexpectedly resolved withdrawal-like symptoms from the cancer drug larotrectinib
A patient experiencing twice-daily withdrawal-like symptoms (myalgias, arthralgias, light sensitivity) from long-term larotrectinib therapy had complete resolution after starting semaglutide, suggesting GLP-1 agonists may modulate TRK-related pain pathways.
Quick Facts
What This Study Found
Long-standing twice-daily withdrawal symptoms from larotrectinib (myalgias, arthralgias, photosensitivity occurring 30-45 min before doses) completely resolved after semaglutide initiation in a patient with >7 years of TRK inhibitor therapy.
Key Numbers
Patient: 35-year-old male with metastatic ETV6-NTRK3 parotid gland cancer. Larotrectinib for 7+ years with complete response. Daily myalgias and arthralgias 30-45 min before next dose. Complete resolution after starting semaglutide.
How They Did This
Single case report documenting clinical timeline of larotrectinib withdrawal symptoms and resolution with semaglutide.
Why This Research Matters
About one-third of patients on TRK inhibitors experience withdrawal-like symptoms that significantly impact quality of life. If GLP-1 agonists can reliably resolve these symptoms, it would improve tolerability of an important cancer therapy.
The Bigger Picture
This unexpected finding highlights that GLP-1 receptors may interact with neurotrophic signaling pathways in ways not previously appreciated. As both TRK inhibitors and GLP-1 agonists become more widely used, understanding their interaction could open new therapeutic applications.
What This Study Doesn't Tell Us
Single case report. No controlled comparison. Cannot establish causation—symptoms may have resolved coincidentally. Mechanism is speculative. Reproducibility unknown.
Questions This Raises
- ?Would semaglutide help other TRK inhibitor patients with withdrawal symptoms?
- ?What is the mechanism by which GLP-1 activation reduces TRK-related pain?
- ?Could other GLP-1 agonists achieve the same effect?
Trust & Context
- Key Stat:
- Complete resolution Seven years of twice-daily withdrawal symptoms from cancer drug larotrectinib completely resolved after starting semaglutide
- Evidence Grade:
- Single case report—lowest evidence level. Intriguing observation requiring prospective validation.
- Study Age:
- Published in 2025; reports a novel and unexpected drug interaction.
- Original Title:
- Larotrectinib-associated withdrawal symptoms resolved following initiation of GLP-1 receptor agonist: a case report.
- Published In:
- Cancer chemotherapy and pharmacology, 95(1), 102 (2025)
- Authors:
- Patel, Reema, Deeken, John F
- Database ID:
- RPEP-12981
Evidence Hierarchy
Describes what happened to one person or a small group.
What do these levels mean? →Frequently Asked Questions
What are TRK inhibitor withdrawal symptoms?
About one-third of patients taking TRK inhibitors (like larotrectinib) for cancer experience withdrawal-like symptoms including muscle pain, joint pain, and light sensitivity when doses are missed, delayed, or wearing off. These occur because TRK pathways are involved in pain signaling.
How might semaglutide help with these symptoms?
The exact mechanism is unclear, but GLP-1 receptors are found in the nervous system and may interact with the neurotrophic pathways that TRK inhibitors target. By modulating these pathways, semaglutide might reduce the pain signals that cause withdrawal-like symptoms between doses.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12981APA
Patel, Reema; Deeken, John F. (2025). Larotrectinib-associated withdrawal symptoms resolved following initiation of GLP-1 receptor agonist: a case report.. Cancer chemotherapy and pharmacology, 95(1), 102. https://doi.org/10.1007/s00280-025-04829-x
MLA
Patel, Reema, et al. "Larotrectinib-associated withdrawal symptoms resolved following initiation of GLP-1 receptor agonist: a case report.." Cancer chemotherapy and pharmacology, 2025. https://doi.org/10.1007/s00280-025-04829-x
RethinkPeptides
RethinkPeptides Research Database. "Larotrectinib-associated withdrawal symptoms resolved follow..." RPEP-12981. Retrieved from https://rethinkpeptides.com/research/patel-2025-larotrectinibassociated-withdrawal-symptoms-resolved
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.